Steel or Plastic: How a Contract Biologics Manufacturer Used Market Research and Consulting to Decide Whether to Convert Its Stainless Steel Capacity to Single-Use Bioreactors

Single-use bioreactor technology changes the economics of contract biologics manufacturing most dramatically at small to mid-scale, where the cleaning validation and sterilisation cycle between campaigns represents a disproportionate share of total turnaround time relative to actual production. A stainless steel vessel that takes four days to clean, validate, and prepare between campaigns is a four-day gap that a single-use system eliminates almost entirely.

The client’s scheduling team was experiencing this problem acutely at its smaller capacity tiers. Early-phase and clinical biotech clients needed short, flexible campaigns with fast turnaround between runs, and the stainless steel vessels at two hundred and five hundred litres were generating scheduling backlogs that were causing the client to decline new business it would otherwise have won.

A further complication was sequencing. Converting trains to single-use required taking them offline, and the wrong order risked disrupting existing client campaigns.

Key Challenges

• No independent market benchmarking of single-use bioreactor turnaround economics at comparable CDMOs across capacity tiers.
• No assessment of which capacity tiers showed the strongest single-use conversion case versus which should remain stainless steel.
• Scheduling backlogs at small-scale tiers causing the client to decline early-phase biotech business it was positioned to win.
• A capital committee requiring evidence-based conversion economics before approving a programme that would take capacity offline.
• No sequencing analysis identifying which trains to convert first without disrupting existing commercial client commitments.
• A strong directional case for conversion but no tier-specific analytics to build a defensible capital proposal.

Single-use bioreactor conversion economics are not uniform across a facility. The case is strongest where turnaround time is a larger share of the total cycle, where campaign flexibility is the competitive differentiator, and where clients are early-phase biotechs rather than established commercial manufacturers. Knowing exactly which capacity tiers those conditions apply to is what separates a defensible capital proposal from a broad technology commitment.